Xtandi (enzalutamide): Insurance Coverage and Denials
A plain-language guide to androgen receptor inhibitor coverage, why insurers deny it, and where to get cancer-specific help.
Xtandi is an oral targeted therapy classified as an androgen receptor inhibitor. It blocks androgen signaling at several points, competing with hormones such as testosterone to prevent activation of the androgen receptor that drives prostate cancer growth. The FDA has approved Xtandi for prostate cancer across several settings, including castration-resistant disease, metastatic castration-sensitive disease, and non-metastatic castration-sensitive disease with biochemical recurrence at high risk for metastasis.
Insurers commonly require prior authorization and often verify the specific prostate cancer setting, prior or concurrent androgen deprivation therapy, and disease status. Because Xtandi is dispensed through specialty pharmacies, denials and delays can also involve routing requirements or requests for additional clinical records.
If coverage is denied, you generally have the right to an internal appeal and then an independent external review under federal protections such as 45 CFR 147.136. For cancer-specific support, contact the PAN Foundation, Patient Advocate Foundation, Triage Cancer, CancerCare, or the Astellas and Pfizer Xtandi copay and patient-assistance programs.
Where to get cancer-specific help
A note on scope. Apellica focuses on appeals for non-oncology insurance denials and does not handle cancer-related appeal cases. Cancer coverage involves complex, fast-moving clinical and financial questions, and patients are best served by organizations built specifically for oncology. If you are facing a cancer drug denial, please reach out to the specialized groups listed on this page, including the PAN Foundation, the Patient Advocate Foundation, Triage Cancer, and CancerCare, along with the manufacturer's own copay or patient-assistance program. They offer free, expert, cancer-focused support, and they can help you understand your options and protect your access to treatment. ---
- PAN Foundation Copay and financial assistance funds for specific diagnoses.
- Patient Advocate Foundation Case managers who help with insurance denials and appeals for serious illness.
- Triage Cancer Free education and resources on cancer-related insurance and appeals.
- CancerCare Professional support services and financial assistance.
Oncology clinics and manufacturers
Apellica partners with infusion centers, oncology practices, and pharmaceutical manufacturers on denial recovery and patient access at scale. If you are exploring a partnership, we would like to talk.
Partner with usFrequently asked questions
- Why do insurers deny Xtandi?
- Staging or castration-status documentation; Line-of-therapy requirements; Prior authorization criteria.
- Can I appeal a Xtandi denial?
- Yes. You generally have the right to an internal appeal and then an independent external review under federal rules such as 45 CFR 147.136. For cancer-specific help, the organizations listed on this page specialize in oncology coverage.